Proteomic Comparison of Bone Marrow Derived Osteoblasts and Mesenchymal Stem Cells.
bone marrow
ex vivo handling
in vitro culture
mesenchymal stem cell
osteoblast
proteome
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
26 May 2021
26 May 2021
Historique:
received:
03
05
2021
revised:
21
05
2021
accepted:
22
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
22
6
2021
Statut:
epublish
Résumé
Mesenchymal stem cells (MSCs) can differentiate into osteoblasts, and therapeutic targeting of these cells is considered both for malignant and non-malignant diseases. We analyzed global proteomic profiles for osteoblasts derived from ten and MSCs from six healthy individuals, and we quantified 5465 proteins for the osteoblasts and 5420 proteins for the MSCs. There was a large overlap in the profiles for the two cell types; 156 proteins were quantified only in osteoblasts and 111 proteins only for the MSCs. The osteoblast-specific proteins included several extracellular matrix proteins and a network including 27 proteins that influence intracellular signaling (Wnt/Notch/Bone morphogenic protein pathways) and bone mineralization. The osteoblasts and MSCs showed only minor age- and sex-dependent proteomic differences. Finally, the osteoblast and MSC proteomic profiles were altered by ex vivo culture in serum-free media. We conclude that although the proteomic profiles of osteoblasts and MSCs show many similarities, we identified several osteoblast-specific extracellular matrix proteins and an osteoblast-specific intracellular signaling network. Therapeutic targeting of these proteins will possibly have minor effects on MSCs. Furthermore, the use of ex vivo cultured osteoblasts/MSCs in clinical medicine will require careful standardization of the ex vivo handling of the cells.
Identifiants
pubmed: 34073480
pii: ijms22115665
doi: 10.3390/ijms22115665
pmc: PMC8198503
pii:
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Wellcome Trust
ID : 100933
Pays : United Kingdom
Références
Stem Cells Dev. 2021 Feb;30(4):214-226
pubmed: 33356875
Front Immunol. 2019 Sep 13;10:2182
pubmed: 31572390
Clin Orthop Relat Res. 2020 Jun;478(6):1307-1315
pubmed: 31899739
Front Cell Dev Biol. 2021 Feb 09;9:598612
pubmed: 33634116
Cell Adh Migr. 2014;8(6):563-77
pubmed: 25482635
Bone. 2009 Feb;44(2):199-207
pubmed: 18845279
J Hematother. 1999 Feb;8(1):63-73
pubmed: 10192303
Haematologica. 2018 May;103(5):810-821
pubmed: 29545342
Ann N Y Acad Sci. 2020 Apr;1466(1):17-23
pubmed: 30767234
Int J Mol Sci. 2018 Jan 25;19(2):
pubmed: 29370110
Stem Cells Int. 2018 Apr 3;2018:1540148
pubmed: 29765406
Leukemia. 2018 Mar;32(3):575-587
pubmed: 28816238
Cell Death Differ. 2016 Jul;23(7):1128-39
pubmed: 26868907
Cancer Metastasis Rev. 2010 Jun;29(2):249-61
pubmed: 20411303
Int J Mol Sci. 2019 Oct 20;20(20):
pubmed: 31635184
J Cell Biochem. 2017 Aug;118(8):1984-1993
pubmed: 28112429
Cancers (Basel). 2018 Jun 04;10(6):
pubmed: 29867053
Bone Res. 2016 Apr 26;4:16009
pubmed: 27563484
Bone. 2015 Jan;70:37-47
pubmed: 25445445
Cancers (Basel). 2020 Dec 28;13(1):
pubmed: 33379263
Bone Res. 2014 Oct 28;2:14034
pubmed: 26273529
Bone Res. 2019 Jan 8;7:2
pubmed: 30622831
Int J Mol Sci. 2020 Oct 15;21(20):
pubmed: 33076329
Immun Inflamm Dis. 2021 Jun;9(2):340-350
pubmed: 33657268
Int J Mol Sci. 2021 Mar 31;22(7):
pubmed: 33807453
Int J Mol Sci. 2020 Jul 23;21(15):
pubmed: 32718092
Cancers (Basel). 2019 Jul 20;11(7):
pubmed: 31330786
Cancer Cell. 2017 Dec 11;32(6):731-747.e6
pubmed: 29232552
J Mol Med (Berl). 2015 Nov;93(11):1203-12
pubmed: 26275789
Nat Med. 2011 Aug 28;17(9):1086-93
pubmed: 21873988
BMC Musculoskelet Disord. 2009 Feb 12;10:20
pubmed: 19216734
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Nature. 2013 Oct 31;502(7473):637-43
pubmed: 24107994
Molecules. 2016 Nov 11;21(11):
pubmed: 27845732
Cancers (Basel). 2021 Mar 25;13(7):
pubmed: 33806032
Biol Blood Marrow Transplant. 2004 Oct;10(10):709-17
pubmed: 15389437
Front Immunol. 2017 Feb 09;8:106
pubmed: 28232835
Stem Cells. 1998;16(5):334-42
pubmed: 9766813
Curr Top Dev Biol. 2016;118:21-44
pubmed: 27137653
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Haematologica. 2004 Apr;89(4):391-402
pubmed: 15075072
Exp Hematol. 2014 Sep;42(9):741-52.e1
pubmed: 24793546
Cancer Immunol Immunother. 2017 Aug;66(8):1059-1067
pubmed: 28501940
Exp Cell Res. 1997 Apr 10;232(1):97-105
pubmed: 9141626
Front Physiol. 2018 May 08;9:504
pubmed: 29867550
Biol Proced Online. 2016 Jun 21;18:13
pubmed: 27330413
Bioengineering (Basel). 2020 Aug 04;7(3):
pubmed: 32759659
Semin Cell Dev Biol. 2016 Jan;49:2-10
pubmed: 26481971
J Cancer Res Clin Oncol. 2005 Jun;131(6):377-84
pubmed: 15776274
Proteomes. 2018 Dec 20;7(1):
pubmed: 30577422
Joint Bone Spine. 2017 Dec;84(6):677-684
pubmed: 28499894
J Clin Endocrinol Metab. 2005 Apr;90(4):2022-8
pubmed: 15687321
J Proteome Res. 2011 Feb 4;10(2):913-20
pubmed: 21067241
J Exp Med. 2011 Mar 14;208(3):421-8
pubmed: 21402747
PLoS One. 2018 Aug 29;13(8):e0202155
pubmed: 30157199
Orthop Surg. 2017 Feb;9(1):13-19
pubmed: 28276640
J Cell Physiol. 2019 Jun;234(6):8082-8093
pubmed: 30548580
Blood. 1996 Sep 1;88(5):1594-607
pubmed: 8781415
Handb Exp Pharmacol. 2020;262:451-473
pubmed: 31820174
BMC Bioinformatics. 2003 Jan 13;4:2
pubmed: 12525261
Nucleic Acids Res. 2017 Jan 4;45(D1):D362-D368
pubmed: 27924014
Bone Jt Open. 2020 Oct 6;1(10):628-638
pubmed: 33215094
Ann Clin Biochem. 2018 May;55(3):308-327
pubmed: 29368538
Nat Methods. 2015 Nov;12(11):1003-4
pubmed: 26513550
Cancers (Basel). 2020 Jul 19;12(7):
pubmed: 32707721
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
Int J Mol Sci. 2017 Aug 25;18(9):
pubmed: 28841158
Nat Protoc. 2019 Jan;14(1):68-85
pubmed: 30464214
Eur Rev Med Pharmacol Sci. 2019 Feb;23(3):1214-1220
pubmed: 30779091
Curr Osteoporos Rep. 2017 Aug;15(4):367-375
pubmed: 28647888
Ann N Y Acad Sci. 2016 Apr;1370(1):5-14
pubmed: 26663266